Page 21 - Hormel Institute Annual Report 2021-22

| 21
Current research projects:
1) Therapeutic potential of mesenchymal stem cell 2) Novel targeted therapies in ovarian cancer
3) AMPK-related proteins in ovarian cancer
4) Cell death and neurogenesis
Recent Publications:
• Chesnokov, M. S., Khan, I., Park, Y., Ezell, J., Mehta, G., Yousif, A., Hong, L. J., Buckanovich, R. J., Takahashi, A., & Chefetz, I. (2021). The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma. Cancers (Basel), 13(6). 1369.
• Golla, N., Hong, L. J., & Chefetz, I. (2021). Visualization of Necroptotic Cell Death through Transmission Electron Microscopy. Methods Mol Biol, 2255, 135-147.
• Chesnokov, M., Khan, I., & Chefetz, I. (2021). Induction and Detection of Necroptotic Cell Death in Mammalian Cell Culture. Methods Mol Biol, 2255, 119-134.
• Takahashi, A., Hong, L., & Chefetz, I. (2020). How to win the ovarian cancer stem cell battle: destroying the roots. Cancer Drug Resist, 3(4), 1021-1033.
• Khan, I., Yousif, A., Chesnokov, M., Hong, L., & Chefetz, I. (2021). A decade of cell death studies: Breathing new life into necroptosis. Pharmacol Ther, 220, 107717.
necroptosis is initiated by TNF-α while Caspases are inhibited using pan-Caspase inhibitor ZVAD-FMK, requires the kinase activity of Receptor-interacting proteins 1 and 3 (RIPK1 and RIPK3) followed by their downstream target MLKL. Necroptosis execution involves formation of micro-complex (20 MDa) necroptosome followed by disintegration of mitochondrial and plasma membranes. Despite the importance of necroptosis, many molecular downstream events are unknown or being disputed.
ORCID iD:
https://orcid.org/0000-0001-6049-0513